Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$105,000.00

Development and testing of the McMaster Cough Severity Questionnaire: a new cough symptom severity instrument for patients with chronic cough

FY 2021-22

Summary
Chronic cough lasting >8 weeks is a common health problem with a global prevalence of 10%. In Canada, chronic cough has a prevalence of 16% and represents one of the most common reasons for referral to a respiratory specialist. Currently, there are no licensed treatments for this condition, but new therapy blocking the actions of ATP on airway nerves is under regulatory review. It is anticipated that this treatment will become available for prescription next year in Canada. Three other ATP blockers are also under investigation for chronic cough. The effectiveness of such therapies in clinical trials have been assessed using 24-hour objective cough frequency. Objective cough monitors are limited, however, in that they are not feasible for use in clinical practice due to expense ($2000 per use) and limited 24-hour recording. Alternative patient reported outcome (PRO) measures to assess the severity of cough and effectiveness of antitussive treatments are urgently needed. Most validated PRO questionnaires for cough assess the impact of cough symptoms on quality of life. A limitation of cough-specific quality of life measures is that they do not assess whether treatment improves severity of the cough symptom itself. This is important because some interventions, such as pregabalin, may reduce the aversiveness and thereby the impact of the cough without improving the underlying problem. Existing PRO measures that assess cough symptom severity have neither been tested for validity or responsiveness, nor made widely available. Therefore, we aim to develop and establish the measurement properties of the McMaster Cough Severity Questionnaire (MCSQ). Development of the MCSQ will provide an important instrument for use in health research and clinical practice to assess the severity of cough and effectiveness of interventions for patients with chronic cough.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
458577
Name
Kum Elena Y
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Development and testing of the McMaster Cough Severity Questionnaire: a new cough symptom severity instrument for patients with chronic cough
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Chronic Cough; Cough Severity; Patient-Reported Outcome
Abstract
Chronic cough lasting >8 weeks is a common health problem with a global prevalence of 10%. In Canada, chronic cough has a prevalence of 16% and represents one of the most common reasons for referral to a respiratory specialist. Currently, there are no licensed treatments for this condition, but new therapy blocking the actions of ATP on airway nerves is under regulatory review. It is anticipated that this treatment will become available for prescription next year in Canada. Three other ATP blockers are also under investigation for chronic cough. The effectiveness of such therapies in clinical trials have been assessed using 24-hour objective cough frequency. Objective cough monitors are limited, however, in that they are not feasible for use in clinical practice due to expense ($2000 per use) and limited 24-hour recording. Alternative patient reported outcome (PRO) measures to assess the severity of cough and effectiveness of antitussive treatments are urgently needed. Most validated PRO questionnaires for cough assess the impact of cough symptoms on quality of life. A limitation of cough-specific quality of life measures is that they do not assess whether treatment improves severity of the cough symptom itself. This is important because some interventions, such as pregabalin, may reduce the aversiveness and thereby the impact of the cough without improving the underlying problem. Existing PRO measures that assess cough symptom severity have neither been tested for validity or responsiveness, nor made widely available. Therefore, we aim to develop and establish the measurement properties of the McMaster Cough Severity Questionnaire (MCSQ). Development of the MCSQ will provide an important instrument for use in health research and clinical practice to assess the severity of cough and effectiveness of interventions for patients with chronic cough.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kum, Elena Y
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McMaster University - $105,000 Grant (2021-22) | Canada Spends